Corporate

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

By

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Advocacy groups add a shade of resistance to Pride celebrations

Advocacy groups add a shade of resistance to Pride celebrations

By

The tone has changed dramatically since last year for LGBT rights groups, which are now as focused on opposing the Trump administration's policies as celebrating progress and community.

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

By By

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Gilead Sciences | 2017

By

Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.

Pfizer | 2017

By

Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.

Johnson & Johnson | 2017

By

After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.

Merck | 2017

By

The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.

Amgen | 2017

By

Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.

Teva Pharmaceutical Industries | 2017

By

The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.

AbbVie | 2017

By

Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.

Sanofi | 2017

By

Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.

Roche | 2017

By

The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.

Novartis | 2017

By

Following one of the most anticipated exclusivity losses of the decade, sales of Novartis cancer drug Gleevec slipped 28% in 2016 to $3.3 billion.

Eli Lilly | 2017

By

Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab.

AstraZeneca | 2017

By

AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.

Five things for pharma marketers to know: Friday, May 26, 2017

Five things for pharma marketers to know: Friday, May 26, 2017

By

FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes

Alexion hires new chief commercial officer

Alexion hires new chief commercial officer

By

Brian Goff is expected to replace Carsten Thiel in June. The drugmaker said Tuesday that Thiel along with several other execs would be leaving the firm.

The class of 2017 wants it all: Work-life balance and a well-paid future

The class of 2017 wants it all: Work-life balance and a well-paid future

By

Recent grads aren't afraid to voice their expectations, and agencies are responding with new programs and policies.

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

By

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

INC Research to buy inVentiv Health in $4.6 billion deal

INC Research to buy inVentiv Health in $4.6 billion deal

By

The deal will create one of the three biggest contract research organizations in the world.

Who Needs a Gold Watch, Anyway?

Who Needs a Gold Watch, Anyway?

Perhaps we should always bear in mind the need to periodically reinvigorate and reshape our careers.

In Merck video, woman says a cure is the greatest invention

In Merck video, woman says a cure is the greatest invention

By

The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira, Trinity Health aim to address opioid use in surgeries

By

Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.

Five things for pharma marketers to know: Monday, March 27, 2017

Five things for pharma marketers to know: Monday, March 27, 2017

By

Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker

P&G exec who led Always #LikeAGirl campaign moves to comms leadership role at Novartis

P&G exec who led Always #LikeAGirl campaign moves to comms leadership role at Novartis

By

P&G's Mark Chakravarty has joined pharma giant Novartis in a senior role.

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

By

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

Industry hires and promotions: February 2017

Industry hires and promotions: February 2017

By

Novo Nordisk appoints new CEO, and more people moves for you to know about

J2 Global considers divesting parts of Everyday Health

J2 Global considers divesting parts of Everyday Health

By

The company acquired Everyday Health in December.

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

By

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer